Aktie A3CM9M ZHAOKE OPHTHALMOLOGY LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Zhaoke Ophthalmology Limited

Aktien

A3CM9M

KYG989M51017

6622

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:07 09.05.2024 		% 5 Tage % 1. Jan.
1.52 HKD +0.66% Intraday Chart für Zhaoke Ophthalmology Limited -3.18% -61.52%
29.04. Zhaoke Ophthalmologie verringert Verlust im Jahr 2023 MT
08.04. Zhaoke Ophthalmology Limited gibt den Rücktritt von Chen Yu Has als Non-Executive Director bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Zhaoke Ophthalmology Shrinks Loss in 2023
Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
Zhaoke Ophthalmology's Investigational New Drug Applications for Pupil-Modulating Eye Drops Given Green Light by Chinese Regulator
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia
Zhaoke Ophthalmology Limited Announces Executive Changes
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China
Zhaoke Ophthalmology Enlists Patients for 2 Drug Trials; Will Refile NDA for Eye Gel
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel
Zhaoke Ophthalmology's Loss Widens in H1
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Zhaoke Ophthalmology Concludes Phase III Trial of Myopia Medication
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial
Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer for the Treatment of Dry Eye Disease
US FDA Approves New Drug Application of Zhaoke Ophthalmology's Eye Drops for Nearsightedness; Shares Surge 12%
Zhaoke Ophthalmology Partner Achieves Positive Top-Line Results from Eye Drop's Phase 3 Trial
Zhaoke Ophthalmology Loss Narrows in 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CM9M Aktie
  4. Nachrichten Zhaoke Ophthalmology Limited
  5. Andere Sprachen